A Comprehensive Guide to 2-Hydroxypropyl-β-Cyclodextrin: Structure, Function, and Pharmaceutical Applications

A Comprehensive Guide to 2-Hydroxypropyl-β-Cyclodextrin: Structure, Function, and Pharmaceutical Applications

Our customer services representatives are available 24 hours a day, from Monday to Sunday.

CONTACT US
Online Inquiry
Verification code
A Comprehensive Guide to 2-Hydroxypropyl-β-Cyclodextrin: Structure, Function, and Pharmaceutical Applications
INQUIRY

What Is 2-Hydroxypropyl-β-Cyclodextrin?

2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) is a chemically modified derivative of natural β-cyclodextrin (β-CD), produced by the hydroxypropylation of β-CD's hydroxyl groups at the 2-, 3-, and/or 6-positions. The structural modification makes HP-β-CD more soluble in water than its parent compound with a solubility rate above 100 mg/mL. The molecule maintains its seven-membered α-1,4-linked D-glucopyranose ring which characterizes β-CD and sustains its conical hydrophobic cavity, but achieves enhanced hydrophilicity through hydroxypropyl substituents. The result is a highly amphiphilic molecule with a hydrophobic inner cavity and a hydrophilic outer surface, making it an ideal inclusion host for hydrophobic guest molecules.

Fig.1 Structure of 2-hydroxypropyl-β-cyclodextrin and its schematic representationFig.1 Structure of 2-hydroxypropyl-β-cyclodextrin (on the left) and its schematic representation (on the right)[1].

The inclusion complexation ability of HP-β-CD is central to its functionality. The hydrophobic cavity accommodates various poorly soluble or unstable substances, while the hydrophilic outer surface enhances their solubility in water and their bioavailability. The molecule's ability to possess both hydrophobic and hydrophilic properties drives its extensive application across pharmaceuticals, biomedical research, cosmetics, food stabilization, and environmental remediation.

How Does HP-β-CD Enhance Drug Solubility, Stability, and Bioavailability?

The top application area for HP-β-CD exists within pharmaceutical formulations. Water solubility problems represent a significant barrier in drug development for almost 40% of newly synthesized chemical entities. HP-β-CD resolves the issue of solubility by using its molecular cavity to encapsulate hydrophobic drugs which enhances solubility and dissolution rate without changing the drugs' chemical composition.

For example, inclusion complexes of HP-β-CD with ketoprofen and dexamethasone have demonstrated significant solubility enhancement, protection from photodegradation, and thermal stability under harsh environmental conditions[2][3]. Moreover, HP-β-CD reduces local toxicity by decreasing direct mucosal or cellular interaction with free drug molecules, thereby improving safety profiles.

Fig.2 The inclusion complex of dexamethasone and HP-β-CD.Fig.2 Structural diagram of the inclusion complex of dexamethasone and HP-β-CD[3].

Additionally, HP-β-CD supports controlled drug release mechanisms. By modulating the binding strength and drug release kinetics, formulators can extend the duration of drug action, reduce dosing frequency, and improve patient compliance. Its low toxicity, favorable safety profile, and regulatory acceptance - including FDA approval for intravenous use - further endorse its utility in advanced drug delivery systems.

Alfa Chemistry offers high-purity HP-β-CD suitable for complex formation in both oral and parenteral drug formulations, supporting improved therapeutic performance.

Catalog Product Name Inquiry
CD128446355(2-Hydroxypropyl)-Beta-CyclodextrinInquiry

How Is HP-β-CD Applied in Biomedical and Neurological Research?

HP-β-CD has demonstrated significant potential beyond conventional pharmaceutical use, particularly in neurodegenerative and lysosomal storage disorders. Its amphiphilic properties allow it to penetrate biological membranes and modulate intracellular cholesterol homeostasis.

In Niemann-Pick Type C1 (NPC1) disease, a genetic lysosomal lipid storage disorder characterized by impaired cholesterol trafficking, HP-β-CD facilitates cholesterol clearance by activating transcription factor EB (TFEB)-mediated autophagy and lysosomal exocytosis.

Fig.3 2-hydroxypropyl-β-cyclodextrin-induced activation of clearance is regulated by TFEBFig.3 HPCD-induced activation of clearance is regulated by TFEB[4].

Notably, HP-β-CD has exhibited the ability to cross into retinal tissues with minimal toxicity, highlighting its potential for ophthalmic drug delivery and neuroretinal therapies[5].

Additionally, HP-β-CD has been observed to selectively induce apoptosis in leukemic cells by disrupting cholesterol-rich microdomains, offering an investigational route for anticancer strategies[6].

What Is the Role of HP-β-CD in Environmental Pollution Control?

HP-β-CD serves as an essential component in environmental cleanup efforts because it can surround hydrophobic pollutants, which results in diminished bioavailability and toxicity as well as reduced persistence within ecosystems. Its inclusion complexation capability extends to various environmental contaminants, including volatile organic compounds (VOCs), persistent organic pollutants (POPs), and flame retardants.

The brominated flame retardant BDE-47 serves as an example since this contaminant exhibits both bioaccumulation tendencies and toxic properties. Research findings indicate that HP-β-CD substantially decreases BDE-47 accumulation in marine organisms, especially Mytilus galloprovincialis (Mediterranean mussels)[7]. HP-β-CD not only lowers tissue-specific concentrations of BDE-47 but also accelerates its elimination and mitigates associated oxidative stress - evidenced by the modulation of antioxidant enzyme activities (e.g., SOD, CAT, GST) and reduced histopathological damage. The molecular docking study demonstrated HP-β-CD's capability to create a stable bond with BDE-47, which protects biological targets from exposure. These findings reinforce HP-β-CD's applicability in water treatment technologies and marine environmental protection.

Fig.4 Structures of BDE-47 included into HPCDFig.5 Optimized structures of BDE-47 included into HPCD[7].

How Is HP-β-CD Used in Food, Cosmetics, and Industrial Applications?

Beyond pharmaceuticals and environmental science, HP-β-CD exhibits remarkable versatility in the food and cosmetic industries. In food preservation, HP-β-CD stabilizes aroma and flavor compounds by preventing volatilization and oxidation. For instance, in oolong tea processing, HP-β-CD complexes have been shown to retain volatile components like cinnamaldehyde, thereby enhancing flavor stability during storage.

In cosmetics, HP-β-CD serves multiple roles: it functions as a stabilizer, deodorizing agent, and active compound carrier. It reduces dermal irritation by limiting the penetration of free irritants while maintaining the activity of volatile or labile bioactives. This encapsulation also minimizes degradation from UV light and oxidation, thus extending product shelf life.

In chemical manufacturing and agriculture, HP-β-CD acts as a solubilizer, emulsifier, and masking agent, improving the efficacy and stability of formulations. Its ability to encapsulate malodorous or reactive compounds makes it ideal for use in advanced material processing and pesticide delivery systems.

What Do We Know About the Safety, Metabolism, and Toxicity of HP-β-CD?

Toxicological evaluations affirm that HP-β-CD is generally well tolerated in both animals and humans[8]. Oral administration in rodents and dogs demonstrates limited systemic toxicity, with only minor biochemical and hematological changes observed in prolonged studies. Intravenous administration, while associated with reversible histopathological changes in organs such as the liver, kidney, and lungs, still yields no observed adverse effect levels (NOAELs) within acceptable safety margins.

Carcinogenicity studies in rats indicated organ-specific tumor formation (e.g., pancreas and intestines), but these effects are species-specific and not predictive of human risk. Embryo-fetal development studies in rats and rabbits revealed no teratogenic or developmental toxicity. In humans, HP-β-CD is well tolerated, with gastrointestinal discomfort, such as diarrhea, being the most commonly reported adverse event. Notably, there is no evidence of renal impairment associated with its use in clinical or investigational settings.

Table 1: Comparison of β-Cyclodextrin and 2-Hydroxypropyl-β-Cyclodextrin Properties

Property β-Cyclodextrin (β-CD) 2-Hydroxypropyl-β-CD (HP-β-CD)
Water Solubility~1.85 g/100 mL>100 g/L
ToxicityHigher hemolytic potentialLow toxicity, FDA-approved
BiodegradabilityBiodegradableBiodegradable
Inclusion CapabilityModerateEnhanced by hydroxypropylation
Parenteral UseLimitedSuitable for IV administration
Regulatory StatusApproved in foodApproved in drug formulations

Alfa Chemistry's extensive collection of cyclodextrin derivatives delivers custom solutions for research and industrial needs across the globe.

References

  1. D'Aria F., et al. (2021). "Thermodynamic properties of hydroxypropyl-β-cyclodextrin/guest interaction: a survey of recent studies." Journal of Thermal Analysis and Calorimetry, 147(8), 1-9.
  2. Chen G., et al. (2007). "Evaluation of 2-Hydroxypropyl-beta-Cyclodextrin as a Solubilizing and Stabilizing Agent for Ketoprofen" Chinese Journal of Modern Applied Pharmacy, (1), 39-42.
  3. Zhang Y., et al. (2008). "Preparation of Hydroxypropyl-β-Cyclodextrin and Its Solubility Improvement on Dexamethasone." Chemcial Industry and Engineering, 25(6): 487-492.
  4. Song W., et al. (2014). "2-Hydroxypropyl-β-cyclodextrin Promotes Transcription Factor EB-mediated Activation of Autophagy." Journal of Biological Chemistry., 289(14), 10211-10222.
  5. Prajapati M., et al. (2021). "Cytotoxicity of β-Cyclodextrins in Retinal Explants for Intravitreal Drug Formulations." Molecules, 26(5), 1492.
  6. Hastings C., et al. (2022). "Intravenous 2-hydroxypropyl-β-cyclodextrin demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial." Mol Genet Metab, 137(4), 309-319.
  7. Liang Z., et al. (2025). "2-Hydroxypropy-β-cyclodextrin reduced the accumulation and toxicity of BDE-47 in Mytilus galloprovincialis." ENVIRONMENTAL CHEMISTRY, 44(2), 666-676.
  8. Gould S., et al. (2005). "22-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review." Food Chem Toxicol, 43(10), 1451-1459.

It should be noted that our our products and services are for research use only, not for clinical use.